Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Septic Shock Management Guided by Ultrasound: SEPTICUS Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04728529
Recruitment Status : Not yet recruiting
First Posted : January 28, 2021
Last Update Posted : January 28, 2021
Sponsor:
Information provided by (Responsible Party):
Saptadi Yuliarto, University of Brawijaya

Brief Summary:
This clinical study aims to compare the recent septic shock management protocol from American College of Critical Care Medicine (ACCM) to Ultrasound-guided Septic Shock Management (USSM) protocol. USSM protocol laid on Doppler ultrasonography to evaluate stroke volume, cardiac index, and systemic vascular resistance in each step of management to decide the proper fluid resuscitation and vasoactive therapy; differs from ACCM protocol which use clinical finding in its early step. ACCM protocol application elicits risk of improper therapy since clinical sign per se often could not describe the certain cardiac output. This can be prevented earlier by USSM protocol. The outcome compared of the two protocols is: mortality rate, clinical parameter, macrocirculation hemodynamic parameter, laboratory microcirculation parameter, and signs of fluid overload. The investigators hypothesized if the USSM protocol had a better outcome and less fluid overload complication.

Condition or disease Intervention/treatment Phase
Septic Shock Procedure: USSM protocol Procedure: ACCM protocol Not Applicable

Detailed Description:

This study is a randomized controlled trial to compare the usage of ACCM protocol and USSM protocol in fluid resuscitation for septic shock pediatric patients. The USSM protocol is the intervention, and the ACCM protocol is the control. This study implemented in septic shock pediatric patients treated in the intensive care unit. Each patient will be randomized into 2 groups, the USSM group or the ACCM group. In the initial step, all patient in each group will receive early acute/emergency therapy: oxygen support, vascular access, and fluid resuscitation. The monitoring of the patient including clinical parameters and laboratory examination for both groups, except Doppler ultrasonography that performed in each step of management of the intervention group. The monitoring is performed every 15 minutes in the first hour of resuscitation. If the patient show good response (fluid responsive shock), the monitoring stops in 1 hour. In contrast, if the patient reveal fluid refractory shock, the vasoactive agent will be administered and monitoring continues until 6 hours. All outcome parameters, except mortality rate, will be recorded at 6 hours. The mortality rates will be recorded at 72 hours and time of intensive care discharge.

Sample size in this study was calculated by clinical trial formula for mortality rate with a significance level of 0.05 and study power of 0.2. From the calculation, the subject needed is 170 patients for each group (total 340 subjects). The basic characteristics of the patient will be analyzed descriptively. All parameter data will be analyzed statistically by Statistical Product and Service Solution (SPSS) 20, preceded by normality test and homogeneity test. The study analysis will be intention-to-treat. The mortality rate was analyzed by Kaplan-Meier survival analysis. Data transformation will be performed if needed in case of outlier data or out-of-range results.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 340 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Each eligible patient will be randomized into 2 groups of treatment, the USSM protocol or the ACCM protocol. All of subjects in each group will receive emergency management: oxygen support, vascular access, and fluid resuscitation. In intervention group, each step of fluid and vasoactive management will be guided by clinical sign and Doppler ultrasonography, whereas in control group only guided by the clinical sign.
Masking: None (Open Label)
Masking Description:

Outcome of mortality rate, macrocirculation hemodynamic parameter, and microcirculation laboratory parameter are objective measurement (does not influenced by assessors's subjectiveness).

However, the assessor of liver enlargement and lung US score will not be masked.

Primary Purpose: Treatment
Official Title: Septic Shock Management Guided by Ultrasound: A Randomized Control Trial (SEPTICUS Trial)
Estimated Study Start Date : March 1, 2021
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock Ultrasound

Arm Intervention/treatment
Experimental: USSM protocol
patient in the intervention group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to USSM protocol of fluid resuscitation.
Procedure: USSM protocol

In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.

The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2


Experimental: ACCM protocol
patient in the control group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to ACCM protocol of fluid resuscitation.
Procedure: ACCM protocol
In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.




Primary Outcome Measures :
  1. Mortality rate [ Time Frame: 72 hours of the initial fluid resuscitation ]
    Time of mortality occurrence since randomization, comparing intervention and control group.

  2. Number of mortality [ Time Frame: 72 hours of the initial fluid resuscitation ]
    Amount of non-survivor subject, comparing intervention and control group.


Secondary Outcome Measures :
  1. Heart rate [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Heart rate is measured by vital sign monitor device, reported in beat/minute, and classified into bradycardia (below normal rate according to age of PALS criteria), normal, and tachycardia (above normal rate according to age of PALS criteria).

  2. Capillary refill time [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Capillary refill time is measured by pressing forehead and sternal skin; time needed for the pink color to return will be measured and reported in second, then classified based on WHO criteria, into prolonged (above 3 seconds) or normal (below or equal than 3 seconds).

  3. Peripheral pulse strength [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Peripheral pulse strength is measured by comparing peripheral radial pulse and central (carotid or femoral) pulse, reported qualitatively as weak or normal/strong

  4. Systolic blood pressure [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Systolic blood pressure is measured by vital sign monitor device and reported in mmHg, and classified into hypotension (below 5th percentiles according to age of PALS criteria), normal (above or equal than 5th percentiles according to age of PALS criteria), and high (above 95th percentiles according to age of PALS criteria).

  5. Mean arterial pressure [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Mean arterial pressure (MAP) is measured by vital sign monitor device and reported in mmHg, and classified into hypotension (below 5th percentiles according to age of PALS criteria), normal (above or equal than 5th percentiles according to age of PALS criteria), and high (above 95th percentiles according to age of PALS criteria).

  6. Systemic vascular resistance index [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Systemic vascular resistance index (SVRI) is measured by USCOM, reported in d.s/cm5/m2, and classified into low (below 800), normal (800 to 1600), and high (above 1600)

  7. Stroke volume index [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Stroke volume index (SVI) is measured by USCOM, reported in mL/m2, and classified into low (below 30), normal (30 to 60), and high (above 60).

  8. Cardiac index [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Cardiac index (CI) is measured by USCOM, reported in L/minute/m2, and classified into low (below 3.3), normal (3.3 to 6.0), and high (above 6.0).

  9. Base deficit [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Base deficit is measured by blood gas analysis examination, reported in mmol/L, and classified into low (below -3), normal (-3 to 3), and high (above 3).

  10. Blood lactate level [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    Blood lactate level is measured from arterial blood, reported in mmol/L, and classified into normal (below or equal to 2.0) or high (above 2.0).

  11. Liver span increase [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]
    The increase of liver span is clinically measured from mid-costal right arch to the edge of liver, and reported in centimeters.

  12. Lung ultrasound score [ Time Frame: 1 hour in fluid-responsive subject or 6 hour in fluid-refractory subject after fluid resuscitation initiated ]

    Lung Ultrasound Score is examined with ultrasound using linear transducer (7.5 to 11 Mhz) to measure pulmonary parenchyma aeration on 12 scan areas (6 areas in each hemithorax), by a doctor who is ultrasound-certified lung. Each hemithorax is divided by 3 vertical lines (parasternal, anterior axillary, and posterior axillary) so that it becomes 3 areas (anterior, lateral, and posterior); and 1 horizontal line dividing the hemithorax into 2 equal parts. In each area a score is recorded. The final result is a total score of 12 areas. The scores are stated as follows:

    i. 0 = no (or very few) B-lines ii. 1 = B-lines look many but separate (separated B-lines) iii. 2 = many B-lines and converge (coalescent B-lines) iv. 3 = lung consolidation




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosed as septic shock according to Pediatric Surviving Campaign (2005)

Exclusion Criteria:

  • patient with uncorrected congenital heart disease with shunting
  • obtain fluid resuscitation before recruitment process
  • obtain inotropic-vasoactive agent before recruitment process
  • after undergo any heart surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04728529


Contacts
Layout table for location contacts
Contact: Saptadi Yuliarto, MD +6281233053652 saptadiy@ub.ac.id
Contact: Nur Hidayati Azhar, MD +62 822-4509-9109 nur.hidayati.azhar@gmail.com

Locations
Layout table for location information
Indonesia
RSUD dr. Saiful Anwar
Malang, Jawa Timur, Indonesia, 65145
Contact: Saptadi Yuliarto, MD    +6281233053652    saptadiy@ub.ac.id   
Sub-Investigator: Kurniawan Taufiq Kadafi, MD         
Sub-Investigator: Nur Hidayati Azhar, MD         
Sponsors and Collaborators
Saptadi Yuliarto
Investigators
Layout table for investigator information
Study Director: Saptadi Yuliarto, MD University of Brawijaya
  Study Documents (Full-Text)

Documents provided by Saptadi Yuliarto, University of Brawijaya:
Informed Consent Form  [PDF] December 30, 2020

Publications:
Davis AL, Carcillo JA, Aneja RK, Deymann AJ, Lin JC, Nguyen TC, Okhuysen-Cawley RS, Relvas MS, Rozenfeld RA, Skippen PW, Stojadinovic BJ, Williams EA, Yeh TS, Balamuth F, Brierley J, de Caen AR, Cheifetz IM, Choong K, Conway E Jr, Cornell T, Doctor A, Dugas MA, Feldman JD, Fitzgerald JC, Flori HR, Fortenberry JD, Graciano AL, Greenwald BM, Hall MW, Han YY, Hernan LJ, Irazuzta JE, Iselin E, van der Jagt EW, Jeffries HE, Kache S, Katyal C, Kissoon N, Kon AA, Kutko MC, MacLaren G, Maul T, Mehta R, Odetola F, Parbuoni K, Paul R, Peters MJ, Ranjit S, Reuter-Rice KE, Schnitzler EJ, Scott HF, Torres A Jr, Weingarten-Arams J, Weiss SL, Zimmerman JJ, Zuckerberg AL. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med. 2017 Jun;45(6):1061-1093. doi: 10.1097/CCM.0000000000002425. Erratum in: Crit Care Med. 2017 Sep;45(9):e993. Kissoon, Niranjan Tex [corrected to Kissoon, Niranjan]; Weingarten-Abrams, Jacki [corrected to Weingarten-Arams, Jacki].

Layout table for additonal information
Responsible Party: Saptadi Yuliarto, Head of Pediatric Emergency and Intensive Care Department, University of Brawijaya
ClinicalTrials.gov Identifier: NCT04728529    
Other Study ID Numbers: University of Brawijaya
First Posted: January 28, 2021    Key Record Dates
Last Update Posted: January 28, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Saptadi Yuliarto, University of Brawijaya:
septic shock
Doppler ultrasonography
Fluid resuscitation
Vasoactive therapy
Mortality rate
Fluid overload
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Septic
Shock
Pathologic Processes
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation